


Guatemala

Region of the Americas




I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	2,260,000	14	Plasmodium species: <i>P. falciparum</i> (0%), <i>P. vivax</i> (100%)
Low transmission (0-1 cases per 1000 population)	10,300,000	62	Major anopheles species: <i>An. albimanus</i> , <i>An. pseudopunctipennis</i> , <i>An. darlingi</i>
Malaria-free (0 cases)	4,060,000	25	Reported confirmed cases (health facility): 4,854 Estimated cases: 6,000 [2,100-12,310]
Total	16,580,000		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: ≤ 10


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted																										
ITN	ITNs/ LLINs distributed free of charge	Yes	2006	First-line treatment of unconfirmed malaria	-	-																										
	ITNs/ LLINs distributed to all age groups	Yes	2006	First-line treatment of <i>P. falciparum</i>	CQ+PQ(1d)	-																										
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	CQ+PQ	-																										
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	-																										
Larval control	Use of larval control recommended	Yes	2005	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-																										
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)																										
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2012	Type of RDT used		P.f + all species (Combo)																										
	Malaria diagnosis is free of charge in the public sector	Yes	-																													
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)																												
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species																					
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-	<table border="1"> <thead> <tr> <th>Insecticide class</th> <th>Years</th> <th>Min</th> <th>Mean</th> <th>Max</th> <th>No. of sites</th> <th>Species</th> </tr> </thead> <tbody> <tr> <td>Organophosphates</td> <td>2011-2011</td> <td>0.8</td> <td>0.9</td> <td>1</td> <td>4</td> <td><i>An. albimanus</i>, <i>An. vestitipennis</i></td> </tr> <tr> <td>Carbamates</td> <td>2011-2011</td> <td>1</td> <td>1</td> <td>1</td> <td>4</td> <td><i>An. albimanus</i>, <i>An. vestitipennis</i></td> </tr> <tr> <td>Pyrethroids</td> <td>2011-2016</td> <td>1</td> <td>1</td> <td>1</td> <td>8</td> <td><i>An. albimanus</i>, <i>An. darlingi</i>, + other</td> </tr> </tbody> </table>	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	Organophosphates	2011-2011	0.8	0.9	1	4	<i>An. albimanus</i> , <i>An. vestitipennis</i>	Carbamates	2011-2011	1	1	1	4	<i>An. albimanus</i> , <i>An. vestitipennis</i>	Pyrethroids	2011-2016	1	1	1	8	<i>An. albimanus</i> , <i>An. darlingi</i> , + other
	Insecticide class	Years	Min		Mean	Max	No. of sites	Species																								
	Organophosphates	2011-2011	0.8		0.9	1	4	<i>An. albimanus</i> , <i>An. vestitipennis</i>																								
	Carbamates	2011-2011	1		1	1	4	<i>An. albimanus</i> , <i>An. vestitipennis</i>																								
Pyrethroids	2011-2016	1	1		1	8	<i>An. albimanus</i> , <i>An. darlingi</i> , + other																									
Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1970																														
G6PD test is a requirement before treatment with primaquine	No	-																														
Directly observed treatment with primaquine is undertaken	Yes	2000																														
Surveillance	System for monitoring adverse reactions to antimalarials exists	Yes	2009																													
	ACD for case investigation (reactive)	Yes	-																													
	ACD of febrile cases at community level (pro-active)	Yes	-																													
	Mass screening is undertaken	Yes	-																													
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-																													
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-																													
Foci and case investigation undertaken	-	-																														
Case reporting from private sector is mandatory	Yes	2000																														



III. Financing



Government expenditure by intervention in 2016



IV. Coverage



V. Impact

